Breast Cancer: evolving landscape of breast cancer biomarkers including emerging markers-FSP Precision Medicine Speaker #3 - Breast Cancer

FSP Precision Medicine Speaker #3 - Breast Cancer - Hatem Soliman

Video Transcription

Video Summary

The talk reviewed how breast cancer biomarkers have rapidly expanded from a few actionable tests to many genomic, proteomic, and pathology-based assays. In early-stage disease, markers such as Oncotype DX, MammaPrint, BCI, germline BRCA/PALB2 testing, and newer tools like Prosigna and digital pathology are being used to guide surgery, radiation, chemotherapy, endocrine therapy, and PARP inhibitor decisions. A major theme was that biomarker development is often outpacing clinical evidence, creating challenges for adoption and interpretation. The speaker highlighted emerging data suggesting Prosigna may help de-escalate chemotherapy in higher-risk groups, and BCI can identify who benefits from extended endocrine therapy. In metastatic disease, biomarkers now strongly guide treatment choice, including ESR1, PIK3CA, AKT/PTEN, HER2, and ctDNA-based monitoring. Overall, biomarkers are increasingly central to personalized breast cancer care, but better validation and decision-support tools are still needed.

Keywords

breast cancer biomarkers

Oncotype DX

MammaPrint

Prosigna

ctDNA monitoring

personalized breast cancer care